Trials / Completed
CompletedNCT04493567
Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe
An Open-label, Randomized, Two-period Cross-over Study to Investigate the Relative Bioavailability of BMS-986036 in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to develop an auto-injector (AI) device for the BMS-986036 subcutaneous formulation that can be self-administered conveniently by participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986036 | Specified dose on specified days |
Timeline
- Start date
- 2020-07-29
- Primary completion
- 2021-06-11
- Completion
- 2021-06-11
- First posted
- 2020-07-30
- Last updated
- 2022-03-18
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04493567. Inclusion in this directory is not an endorsement.